ArticleMedicine2026
Network pharmacology and molecular dynamics study of Astragalus membranaceus-Salvia miltiorrhiza in the treatment of myocardial ischemia-reperfusion injury.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial ischemia-reperfusion injury (MIRI) represents a significant complication associated with revascularization treatment for individuals experiencing a myocardial infarction. Studies have demonstrated that both Astragalus membranaceus and Salvia miltiorrhiza (AS) exhibit cardioprotective properties. This study investigates the potential mechanisms of AS in treating MIRI through network pharmacology, molecular docking, and molecular dynamics simulations. In this investigation, the active compounds and their corresponding targets linked to AS were obtained from the traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP), as well as from the PubChem and SwissTargetPrediction databases, while the target genes for MIRI were sourced from the GeneCards and OMIM databases. A protein-protein interaction network was created using STRING and Cytoscape to identify core targets. Utilizing the DAVID database, enrichment analyses through gene ontology and the kyoto encyclopedia of genes and genomes were performed to clarify pathways associated with the therapeutic application of AS in managing MIRI. AutoDockTools was utilized to assess the binding affinity of key bioactive compounds with major targets, complemented by molecular dynamics simulations using GROMACS. Results indicated that AS contains 85 bioactive compounds, 803 drug-target genes, and 1451 disease targets, with 136 intersecting targets and 28 core targets identified. Molecular docking results showed that the core targets successfully docked with major pharmacological components, with more stable binding observed between AKT1 and luteolin, PTGS2 and luteolin, PTGS2 and kaempferol. Molecular dynamics simulation results indicated good stability. Through the utilization of network pharmacology, molecular docking, and molecular dynamics simulations, this research establishes that AS can deliver therapeutic benefits for MIRI by acting on various components, targets, and pathways, thereby offering a theoretical basis for future investigations and clinical implementations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.